- BGN198.80m
- BGN382.36m
- BGN1.68bn
- 73
- 95
- 57
- 89
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.61 | ||
| Price to Tang. Book | 2.35 | ||
| Price to Free Cashflow | 6 | ||
| Price to Sales | 0.12 | ||
| EV to EBITDA | 4.99 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 21.44% | ||
| Return on Equity | 26.84% | ||
| Operating Margin | 2.65% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | BGNm | 958.69 | 1,165.42 | 1,344.01 | 1,487.41 | 1,681.1 | n/a | n/a | 13.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +4.62 | +15.96 | +16.77 | -4.01 | +31.53 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sopharma Trading AD (Sofarma Trading AD) is a Bulgaria-based company that is principally engaged in the distribution and wholesale of pharmaceuticals, drugs, medical supplies and facilities, food additives, vitamins and disinfectants. Its product portfolio includes more than 7,000 items. The Company operates warehouses and regional distributive centers in five cities in Bulgaria, the Company supplies its products to pharmacies, hospitals, clinics and other health care facilities. Sopharma Trading AD Sofia is a part of the Sopharma Group. As of December 31, 2011, the Company’s major shareholder was Sopharma AD with a stake of 81.33%.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 24th, 2005
- Public Since
- January 30th, 2008
- No. of Employees
- 2,616
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Bulgarian Stock Exchange- Shares in Issue
- 34,276,050
- Address
- ul. Lachezar Stanchev No. 5, SOFIA, 1756
- Web
- https://www.sopharmatrading.com/?lang=bg
- Phone
- +359 28133660
- Contact
- Ventsislav Marinov
- Auditors
- Baker Tilly Klitou
Upcoming Events for SFT
Similar to SFT
Tchaikapharma High Quality Medicines AD
Bulgarian Stock Exchange
FAQ
As of Today at 19:20 UTC, shares in Sopharma Trading AD are trading at BGN5.80. This share price information is delayed by 15 minutes.
Shares in Sopharma Trading AD last closed at BGN5.80 and the price had moved by over the past 365 days. In terms of relative price strength the Sopharma Trading AD share price has underperformed the FTSE Global All Cap Index by -10.76% over the past year.
The overall consensus recommendation for Sopharma Trading AD is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Sopharma Trading AD does not currently pay a dividend.
Sopharma Trading AD does not currently pay a dividend.
Sopharma Trading AD does not currently pay a dividend.
To buy shares in Sopharma Trading AD you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of BGN5.80, shares in Sopharma Trading AD had a market capitalisation of BGN198.80m.
Here are the trading details for Sopharma Trading AD:
- Country of listing: Bulgaria
- Exchange: BLG
- Ticker Symbol: SFT
Based on an overall assessment of its quality, value and momentum Sopharma Trading AD is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sopharma Trading AD. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -18.54%.
As of the last closing price of BGN5.80, shares in Sopharma Trading AD were trading -2.59% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sopharma Trading AD PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at BGN5.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sopharma Trading AD's management team is headed by:
- Ognian Donev - CHM
- Dimitar Dimitrov - CEO
- Ventsislav Marinov - DCE
- Angel Yordanov - DRC